학술논문
Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
Document Type
Article
Author
Source
In The Lancet Gastroenterology & Hepatology February 2023 8(2):133-144
Subject
Language
ISSN
2468-1253